Retatrutide vs SNAP-8
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →SNAP-8
SNAP-8 (Acetyl Octapeptide-3) is a cosmetic peptide that reduces the appearance of wrinkles by modulating muscle contraction. It is often called 'topical Botox' though it works through a different mechanism.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | SNAP-8 |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Mimics the N-terminal end of SNAP-25, competing with native SNAP-25 for position in the SNARE complex. This reduces neurotransmitter release at the neuromuscular junction, decreasing muscle contraction. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Topical: 3-10% concentration in serums or creams, applied 1-2 times daily to target areas (forehead, crow's feet, etc.). |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Topical application only. Should be applied to clean skin. Often formulated with penetration enhancers for better absorption. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Generally well-tolerated topically. Rare reports of mild skin irritation. No systemic effects at cosmetic doses. |
| Best For |